Abstract:Ezrin, a member of the ezrin/radixin/moesin (ERM) protein family, plays an important role in tumor metastasis. Accumulating studies demonstrated that a high expression level of human ezrin has been correlated with numerous human malignancies. This study was aimed to explore the clinicopathological significance of ezrin protein expression in pancreatic ductal adenocarcinomas (PDAC), and to further identify its role as a potential biomarker and therapeutic target of PDAC. Immunohistochemical (IHC) staining of ezrin protein was performed on 106 PDAC tissue samples and 37 adjacent and 21 normal pancreatic tissue samples. Additionally, localization of ezrin protein in Panc-1 PDAC cell line was observed using immunofluorescence (IF) staining. The correlation between ezrin overexpression and the clinicopathological features of PDAC was evaluated using Chi-square test, and differences in survival curves were analyzed using log-rank tests. In results, ezrin protein is widely distributed in the cytoplasm and membrane of PDAC cells by IHC and IF staining, but some cases showed a cell membrane staining pattern. The positive rate of ezrin protein expression was 82.1% (87/106) in PDAC, which was significantly higher than it in either adjacent pancreatic tissues (37.8%, 14/37) or normal pancreatic tissues (19.0%, 4/21). Overexpression of ezrin was closely related with larger tumor size, positive lymph node metastasis and advanced clinical stage. However, it was not correlated with patient age, gender, differentiation, Ki-67 expression index, and pancreas calcification point. Survival analysis showed that patients with ezrin high expression level had significantly lower overall survival rate than that with ezrin low expression level. Importantly, further analysis using a Cox proportional hazard regression model revealed that high ezrin expression emerged as a significant independent hazard factor for overall survival rates of patients with PDAC along with lymph node metastasis and TNM stage. In conclusion, ezrin protein played an important role in the progression of PDAC, and the overexpression of ezrin protein might be a useful prognostic marker of PDAC.

Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma

Identification of MYEOV-Associated Gene Network as a Potential Therapeutic Target in Pancreatic Cancer

High expression of MYEOV reflects poor prognosis in non-small cell lung cancer

Comprehensive Analysis of Myoferlin in Human Pancreatic Cancer Via Bioinformatics

MYEOV overexpression induced by demethylation of its promoter contributes to pancreatic cancer progression via activation of the folate cycle/c-Myc/mTORC1 pathway

Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma

Integrated Expression Profiles Analysis Reveals Novel Predictive Biomarker in Pancreatic Ductal Adenocarcinoma

Analysis of Methylation‐driven Genes in Pancreatic Ductal Adenocarcinoma for Predicting Prognosis

Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer.

Ott_a_195675 4153..4165

Ezrin Protein Overexpression Predicts the Poor Prognosis of Pancreatic Ductal Adenocarcinomas.

Machine Learning Developed a MYC Expression Feature-Based Signature for Predicting Prognosis and Chemoresistance in Pancreatic Adenocarcinoma

Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis

MYEOV with High Frequencies of Mutations in Head and Neck Cancers Facilitates Cancer Cell Malignant Behaviors

Elevated Expression of Cell Adhesion, Metabolic, and Mucus Secretion Gene Clusters Associated with Tumorigenesis, Metastasis, and Poor Survival in Pancreatic Ductal Adenocarcinoma

Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in Tumor Tissues Predicts Poor Survival in Pancreatic Ductal Adenocarcinoma.

Overexpression of EFEMP1 Correlates with Tumor Progression and Poor Prognosis in Human Ovarian Carcinoma

The Low Expression of MEOX2 is Associated With Poorer Survival in Breast Cancer

DEK Protein Overexpression Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

Integrated Analysis Identifies MEOX2 as a Malignant Driver and Prognostic Biomarker in Brain Glioma

Overexpression and Biological Function of MEF2D in Human Pancreatic Cancer.